| Latest Verona Pharma News Headlines |
| Date | Time | Source | |
| 11/11/2008 | 11:47AM | UKREG | Holding(s) in Company
RNS Number : 9529H
Verona Pharma PLC
11 November 2008
Verona Pharma plc
(the "Company")
Notice of interest
The Company announces that it has today received notification that following a disposal of shares on 10 November, 2008, Integrated Core
Strategies (Europe) S.a.r.l. is now... More...>> |
| 09/23/2008 | 3:28AM | TFNF | Verona Pharma H1 pretax loss widens on higher R&D costs
Verona Pharma Plc., the AIM-quoted respiratory
disease specialist, said its first half pretax loss widened on higher research
and development costs.
The company added that it is continuing to identify projects of interest.
For the six months to end-June, Verona Pharma posted a pretax loss of
637,926... More...>> |
| 09/23/2008 | 2:01AM | UKREG | Half-yearly Report
VERONA PHARMA PLC
('Verona Pharma' or the 'Company')
Verona Pharma, the AIM-quoted company developing new therapeutic drugs for the
treatment of respiratory diseases, today announces its Interim Results for the
six months to 30 June... More...>> |
| 09/09/2008 | 2:24AM | TFNF | BRIEF-Verona to begin human trials with hay fever drug
LONDON, Sept 9 (Reuters) - Verona Pharma Plc:
* Says signed a deal to begin clinical trials with rpl554, its potential
ground-breaking
drug for the treatment of asthma and allergic rhinitis (hay fever
((London Equities Newsroom; +44 20 7542 7717))
tf.TFN-Europe_newsdesk@thomson.com
vs
COPYRIGHT
Copyright... More...>> |
| 09/09/2008 | 2:00AM | UKREG | Update on Clinical Trials
For release 07.00, 9 September 2008
Verona Pharma
Verona Pharma signs to begin human clinical trials for potential anti-asthma
drug
The AIM-quoted drug discovery company... More...>> |
| 07/31/2008 | 2:00AM | UKREG | Total Voting Rights
Verona Pharma plc
(the "Company")
Total Voting Rights
For the purposes... More...>> |
| 07/07/2008 | 12:10PM | UKREG | Issue of Equity
Verona Pharma plc
(the "Company")
Issue of Equity
The Company announces that, following the exercise of 7,940,000 options at 2p
each and 1,000,000 options... More...>> |
| 06/18/2008 | 2:44AM | TFNF | Verona Pharma says launched collaboration agreement with GlycoMar Ltd
Verona Pharma Plc, the AIM-quoted respiratory
disease specialist, has announced a collaboration agreement with GlycoMar
Limited, a Scottish marine marine biotechnology company with which it previously
had a service agreement.
Under the new collaboration agreement, Verona is progressing a number of new
compounds... More...>> |
| 06/18/2008 | 2:00AM | UKREG | New Agreement
VERONA PHARMA PLC
("Verona Pharma" or the "Company")
Verona... More...>> |
| 05/28/2008 | 12:44PM | UKREG | Issue of Equity
Verona Pharma plc
(the "Company")
Issue of Equity
The Company announces that, following the exercise of 210,000 options at 2p
each, the Company has... More...>> |
| 05/23/2008 | 11:36AM | UKREG | Result of AGM
RNS Number : 2187V
Verona Pharma PLC
23 May 2008
Verona Pharma plc
("the Company")
Result of AGM
The Company is pleased to announce that at the Annual General Meeting held today all resolutions were duly passed.
A copy of a presentation given at the Annual General Meeting... More...>> |
| 05/19/2008 | 10:20AM | TFNF | Verona Pharma says respiratory candidate passes crucial safety, toxicology tests
Verona Pharma Plc. said the compound RPL554, an
anti-inflammatory drug being developed for the treatment of hay fever and
asthma, has passed crucial safety and toxicology tests.
The AIM-quoted drug discovery company added it is completing the
documentation needed to obtain regulatory approval for the commencement... More...>> |
| 05/19/2008 | 10:18AM | UKREG | Planned asthma and hay fever drug passes crucial tests
Verona Pharma plc
("Verona Pharma" or the "Company")
Planned anti-asthma and hay fever treatment passes crucial tests
A new treatment for respiratory diseases such as asthma and hay fever has
passed pivotal safety and... More...>> |
| 05/19/2008 | 4:11AM | TFNF | Verona Pharma says respiratory candidate passes crucial safety, toxicology tests
Verona Pharma Plc. said the compound RPL554, an
anti-inflammatory drug being developed for the treatment of hay fever and
asthma, has passed crucial safety and toxicology tests.
The AIM-quoted drug discovery company added it is completing the
documentation needed to obtain regulatory approval for the commencement... More...>> |
| 05/19/2008 | 2:01AM | UKREG | Planned asthma and hay fever drug passes crucial tests
Verona Pharma plc
("Verona Pharma" or the "Company")
Planned anti-asthma and hay fever treatment passes crucial tests
A new treatment for respiratory diseases such as asthma and hay fever has
passed pivotal safety and... More...>> |
| 05/19/2008 | 2:01AM | UKREG | Planned asthma and hay fever drug passes crucial tests
Verona Pharma plc
("Verona Pharma" or the "Company")
Planned anti-asthma and hay fever treatment passes crucial tests
A new treatment for respiratory diseases such as asthma and hay fever has
passed pivotal safety and... More...>> |
| 05/14/2008 | 2:00AM | UKREG | Issue of Equity
Verona Pharma plc
(the "Company")
Issue of Equity
The Company announces that, following the exercise of options over 1,250,000
ordinary shares of 0.1p each... More...>> |
| 04/30/2008 | 4:18AM | UKREG | Issue of Equity
Verona Pharma PLC
30 April 2008
Verona Pharma plc
(the "Company")
Issue of Equity
The Company announces that, following the exercise of 100,000 options at 2p
each, the Company has issued 100,000 new ordinary... More...>> |
| 04/02/2008 | 3:29AM | TFNF | Verona Pharma posts wider full-year pretax loss, sees research progress
Verona Pharma Plc. posted a wider full-year
pretax loss but said it sees significant progress in its research programmes in
2008.
For the year ended Dec. 31, the company reported a pretax loss of 1.22
million pounds versus a loss of 608,391 pounds the previous year.
Research and development expenses... More...>> |
| 04/02/2008 | 2:01AM | UKREG | 2007 Preliminary Financial Results
VERONA PHARMA plc
("Verona Pharma" or the "Company")
PRELIMINARY AUDITED RESULTS
for the twelve months ended 31 December 2007
Verona Pharma plc is a life... More...>> |